Logo image of CUE

CUE BIOPHARMA INC (CUE) Stock Fundamental Analysis

NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD

0.7051  +0.03 (+4.86%)

Fundamental Rating

3

CUE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 555 industry peers in the Biotechnology industry. The financial health of CUE is average, but there are quite some concerns on its profitability. CUE shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CUE had negative earnings in the past year.
CUE had a negative operating cash flow in the past year.
In the past 5 years CUE always reported negative net income.
CUE had a negative operating cash flow in each of the past 5 years.
CUE Yearly Net Income VS EBIT VS OCF VS FCFCUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CUE's Return On Assets of -182.37% is on the low side compared to the rest of the industry. CUE is outperformed by 87.75% of its industry peers.
The Return On Equity of CUE (-616.78%) is worse than 80.00% of its industry peers.
Industry RankSector Rank
ROA -182.37%
ROE -616.78%
ROIC N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
CUE Yearly ROA, ROE, ROICCUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CUE Yearly Profit, Operating, Gross MarginsCUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

4

2. Health

2.1 Basic Checks

CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CUE has been increased compared to 1 year ago.
The number of shares outstanding for CUE has been increased compared to 5 years ago.
The debt/assets ratio for CUE is higher compared to a year ago.
CUE Yearly Shares OutstandingCUE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CUE Yearly Total Debt VS Total AssetsCUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -26.07, we must say that CUE is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -26.07, CUE is doing worse than 88.65% of the companies in the same industry.
CUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -26.07
ROIC/WACCN/A
WACC8.88%
CUE Yearly LT Debt VS Equity VS FCFCUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

CUE has a Current Ratio of 1.03. This is a normal value and indicates that CUE is financially healthy and should not expect problems in meeting its short term obligations.
CUE's Current ratio of 1.03 is on the low side compared to the rest of the industry. CUE is outperformed by 87.39% of its industry peers.
CUE has a Quick Ratio of 1.03. This is a normal value and indicates that CUE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.03, CUE is doing worse than 86.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
CUE Yearly Current Assets VS Current LiabilitesCUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

CUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.38%, which is quite impressive.
The Revenue has grown by 13.86% in the past year. This is quite good.
The Revenue has been growing by 21.83% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)37.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32%
Revenue 1Y (TTM)13.86%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%-75.48%

3.2 Future

CUE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.97% yearly.
The Revenue is expected to grow by 100.29% on average over the next years. This is a very strong growth
EPS Next Y20.55%
EPS Next 2Y18.92%
EPS Next 3Y10.25%
EPS Next 5Y33.97%
Revenue Next Year-14.18%
Revenue Next 2Y3.09%
Revenue Next 3Y29.64%
Revenue Next 5Y100.29%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CUE Yearly Revenue VS EstimatesCUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CUE Yearly EPS VS EstimatesCUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
Also next year CUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUE Price Earnings VS Forward Price EarningsCUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUE Per share dataCUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.92%
EPS Next 3Y10.25%

More info and screens

0

5. Dividend

5.1 Amount

CUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CUE BIOPHARMA INC

NASDAQ:CUE (7/2/2025, 3:43:03 PM)

0.7051

+0.03 (+4.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners15.2%
Inst Owner Change-3.31%
Ins Owners0.35%
Ins Owner Change0%
Market Cap53.13M
Analysts85.71
Price Target4.08 (478.64%)
Short Float %1.11%
Short Ratio4.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.86%
Min EPS beat(2)-9.77%
Max EPS beat(2)17.49%
EPS beat(4)3
Avg EPS beat(4)12.64%
Min EPS beat(4)-9.77%
Max EPS beat(4)30.27%
EPS beat(8)6
Avg EPS beat(8)12%
EPS beat(12)9
Avg EPS beat(12)9.02%
EPS beat(16)11
Avg EPS beat(16)9.97%
Revenue beat(2)0
Avg Revenue beat(2)-37.69%
Min Revenue beat(2)-67.11%
Max Revenue beat(2)-8.27%
Revenue beat(4)2
Avg Revenue beat(4)36.53%
Min Revenue beat(4)-67.11%
Max Revenue beat(4)117.33%
Revenue beat(8)6
Avg Revenue beat(8)41.96%
Revenue beat(12)7
Avg Revenue beat(12)8.89%
Revenue beat(16)10
Avg Revenue beat(16)24.9%
PT rev (1m)14.29%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.91%
EPS NY rev (3m)-7.27%
Revenue NQ rev (1m)49.97%
Revenue NQ rev (3m)49.97%
Revenue NY rev (1m)36.48%
Revenue NY rev (3m)-22.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.65
P/FCF N/A
P/OCF N/A
P/B 8.07
P/tB 8.07
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0.11
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -182.37%
ROE -616.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.96%
ROA(5y)-72.96%
ROE(3y)-149.98%
ROE(5y)-114.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.35%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z -26.07
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)11.7%
Cap/Depr(5y)32.79%
Cap/Sales(3y)4.77%
Cap/Sales(5y)7.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32%
EPS Next Y20.55%
EPS Next 2Y18.92%
EPS Next 3Y10.25%
EPS Next 5Y33.97%
Revenue 1Y (TTM)13.86%
Revenue growth 3Y-14.66%
Revenue growth 5Y21.83%
Sales Q2Q%-75.48%
Revenue Next Year-14.18%
Revenue Next 2Y3.09%
Revenue Next 3Y29.64%
Revenue Next 5Y100.29%
EBIT growth 1Y19.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.47%
OCF growth 3YN/A
OCF growth 5YN/A